RSS
EUSA Pharma
NICE recommends tivozanib as first-line treatment for kidney cancer
The National Institute for Health and Care Excellence (NICE) has published a Final Appraisal Determination (FAD) recommending tivozanib as a first-line treatment option for advanced renal cell carcinoma (aRCC) in line with its licensed indication more
